Skip to main content
. 2015 Jan 6;10:69–77. doi: 10.2147/COPD.S73521

Figure 2.

Figure 2

Questionnaire on adverse events 8 weeks after switching from the HandiHaler inhaler to the Respimat inhaler.

Notes: Respimat had a significantly milder aftertaste than the HandiHaler (P=0.004), but there were no other significant differences in the incidence of adverse events (question 4: Please indicate whether you experienced any of the following symptoms after using each device).